Last Updated: November 16, 2026

Details for Patent: 10,889,587

« Back to Dashboard


Which drugs does patent 10,889,587 protect, and when does it expire?

Patent 10,889,587 protects UTEBZI and is included in one NDA.

This patent has thirty-two patent family members in twenty-five countries.

Summary for Patent: 10,889,587
Title:Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
Abstract:The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.
Inventor(s):Akash Jain, Evan Hecker, Richard Edwards, Thierry Bonnaud
Assignee: Spero Therapeutics Inc
Application Number:US16/483,989
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

U.S. Patent 10,889,587: Tebipenem Pivoxil Hydrobromide Claims, Scope and Patent Landscape

U.S. Patent No. 10,889,587 protects crystalline forms of tebipenem pivoxil hydrobromide, particularly forms identified by powder X-ray diffraction and differential scanning calorimetry. Its commercial importance is concentrated in the solid-state active pharmaceutical ingredient, pharmaceutical compositions containing at least 90% of that form, oral and other dosage forms, and treatment of bacterial infections, including complicated urinary tract infections.

The patent does not claim tebipenem pivoxil broadly in every chemical form. Its principal limitation is the specific crystalline hydrobromide form defined by the claimed XPRD pattern. The patent was issued to Spero Therapeutics, Inc. and is associated with the company’s oral tebipenem development program.

What does U.S. Patent 10,889,587 protect?

The patent has four operative protection layers:

Protection layer Relevant claims Scope
Crystalline API form 1-5 Tebipenem pivoxil hydrobromide characterized by XPRD and DSC
Pharmaceutical composition 6, 12-13 Composition containing at least 90% of the claimed crystalline form, optionally with another active agent
Dosage form 7-8 Intravenous, injectable, topical, oral, tablet or capsule forms
Therapeutic use 9-11, 14-16 Treatment of bacterial infections, including urinary tract and specified Gram-negative infections

The core commercial claim is claim 2. Claims 1 and 3-5 provide alternative or narrower analytical definitions of the same crystalline subject matter.

How is the claimed crystalline form defined?

The claims identify the form through X-ray powder diffraction, or XRPD/XPRD, using a copper K-alpha radiation source.

Claim 1 refers to the characteristic 2θ values shown in Figure 14. Claim 2 provides two alternative peak sets:

  1. Peaks at approximately 9.3°, 13.0°, 17.6°, 20.8° and 26.8° 2θ; or
  2. Peaks at approximately 10.7°, 14.0°, 18.7°, 20.0° and 23.5° 2θ.

The stated tolerance is ±0.2° 2θ. Claim 3 requires the combined set of ten peaks:

9.3°, 10.7°, 13.0°, 14.0°, 17.6°, 18.7°, 20.0°, 20.8°, 23.5° and 26.8° 2θ.

Claim 4 adds a DSC profile substantially corresponding to Figure 15. Claim 5 narrows the form by specifying a first endotherm with an onset of 32.9°C and a minimum at 66.3°C, followed by a second endotherm with an onset of 186.8°C and a maximum at 190.8°C.

The practical consequence is that infringement depends on analytical identity, not merely on the presence of tebipenem pivoxil or hydrobromide. A competing manufacturer using a different salt, amorphous material, polymorph, hydrate, solvate or crystalline form may avoid the literal API claims, subject to equivalents and the composition and method claims.

What is the claim-by-claim scope?

Claims 1-5: crystalline tebipenem pivoxil hydrobromide

Claims 1-5 are composition-of-matter claims directed to a solid-state form.

Claim 1 is figure-dependent. It incorporates the characteristic diffraction pattern shown in Figure 14. Its enforceability will depend on whether Figure 14 gives sufficiently definite and reproducible peak information.

Claim 2 is the principal independent crystalline-form claim. Its alternative peak groupings broaden the claim beyond a single complete diffractogram. A product could potentially fall within claim 2 if it exhibits either specified five-peak group, even if its full pattern differs in other respects.

Claim 3 is narrower than claim 2 because it requires all ten listed peaks.

Claims 4 and 5 add DSC limitations. Claim 5 is especially useful for analytical comparison because it identifies thermal transitions numerically rather than by reference only to a figure.

A technical infringement investigation would normally compare:

  • XRPD peak positions;
  • relative peak intensities;
  • radiation source and instrument conditions;
  • sample preparation;
  • polymorphic conversion during milling, drying or formulation;
  • DSC onset, minimum and maximum temperatures;
  • water or solvent content; and
  • salt stoichiometry and residual reagents.

Claims 6-8: pharmaceutical compositions and dosage forms

Claim 6 requires a pharmaceutical composition comprising:

  • a tebipenem pivoxil salt;
  • a physiologically acceptable carrier; and
  • at least 90% of the crystalline tebipenem pivoxil hydrobromide form claimed in claim 2.

The “at least 90%” limitation is a meaningful boundary. It may refer to the proportion of the claimed crystalline form in the tebipenem pivoxil salt component, rather than 90% of the entire finished dosage form. The specification and prosecution history would control how that phrase is construed.

Claim 7 extends the composition to intravenous, injectable, topical or oral dosage forms. Claim 8 narrows the dosage form to a tablet or capsule. For the intended oral product, claim 8 is commercially more relevant than the parenteral and topical alternatives.

The composition claims can create infringement exposure even if a manufacturer does not sell the crystalline API as a standalone product. A tablet or capsule containing the claimed form may infringe if the 90% threshold is met.

Claims 9-16: treatment and combination therapy

Claim 9 covers administering a therapeutically effective amount of the crystalline form to treat a bacterial infection. Claim 10 limits the patient to a human. Claim 11 specifies urinary tract infection.

Claims 12-15 address combination therapy. They cover a composition or treatment involving a second active agent, with an antibiotic identified as the narrower category.

Claim 16 lists infections caused by:

  • Gram-negative bacteria;
  • Escherichia coli;
  • Klebsiella pneumoniae;
  • Acinetobacter baumannii;
  • Pseudomonas aeruginosa;
  • Neisseria gonorrhoeae; or
  • Yersinia pestis.

Claim 16 contains a drafting issue because it refers to “the method of claim 6,” although claim 6 is a composition claim. That apparent dependency defect could affect claim construction and validity. A court could treat the reference as an obvious typographical error if the intended dependency is clear from the specification and prosecution record, or could refuse to correct it if the error creates substantive ambiguity.

How strong is the patent estate?

The strongest part of the patent is the crystalline-form protection in claims 2 and 3. Solid-state claims can block a generic manufacturer from copying the sponsor’s selected API form, even where the underlying active ingredient is known.

The estate is weaker in the following areas:

Issue Risk assessment
Broad API exclusivity Limited. The claims do not cover all tebipenem pivoxil salts or all tebipenem formulations.
Alternative polymorphs A material risk to the patent holder if a non-infringing form can meet stability and manufacturing requirements.
XRPD variability Moderate claim-construction risk because peak positions can shift with instrumentation and sample conditions.
Composition claims Potentially strong for an approved product using the claimed form, subject to the 90% interpretation.
Method claims Commercially useful but may be difficult to enforce against unobserved prescribing or manufacturing conduct.
Claim 16 Drafting and dependency risk.
Manufacturing control Strong practical barrier if the claimed form is the only form with acceptable stability, bioavailability or process performance.

The patent’s practical value therefore depends on whether the claimed form is necessary for the commercial product or is merely one interchangeable solid-state option.

When does U.S. Patent 10,889,587 lose exclusivity?

The patent issued on January 12, 2021. Patent expiration is not determined by the grant date. The relevant term generally runs 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, terminal disclaimers and any applicable patent-term extension under 35 U.S.C. § 156.

The publicly associated tebipenem crystalline-form application has a mid-2010s priority history. On that basis, the unadjusted statutory term would be expected to fall in the mid-2030s, subject to the USPTO’s official term calculation. FDA regulatory exclusivity, if granted for an approved product, would run separately from the patent term and would not automatically extend the patent.

Event Date or timing
Earliest development and patent priority period Mid-2010s
U.S. patent grant January 12, 2021
Base patent term Expected to extend into the mid-2030s
Patent-term adjustment Must be added if awarded by USPTO
Regulatory exclusivity Separate FDA determination
Generic launch Earliest lawful date depends on patent term, listed patents, litigation and regulatory exclusivity

A precise expiration date should be taken from the USPTO Patent Center term-adjustment record and the patent’s front-page term information, not inferred solely from the issue date.

What is the Orange Book status of tebipenem pivoxil hydrobromide?

Tebipenem pivoxil hydrobromide has not established the same Orange Book litigation profile as an approved, commercially marketed small-molecule antibiotic. The Orange Book lists approved drug products and patents submitted by sponsors under the Hatch-Waxman framework. A patent becomes strategically important in an ANDA dispute only if it is listed against an approved reference product and remains eligible for listing.

The relevant regulatory history is:

Regulatory issue Status
Active ingredient Tebipenem pivoxil hydrobromide
Sponsor Spero Therapeutics
Intended indication Complicated urinary tract infection, including pyelonephritis
FDA pathway NDA for an oral carbapenem
Approval status No approved U.S. product had been established through the available FDA record
Orange Book litigation No mature Paragraph IV litigation profile identified
Biosimilar pathway Not applicable; this is a chemically synthesized small molecule
Generic pathway Potential ANDA pathway after approval and applicable exclusivity

Spero received a complete response letter for its tebipenem program in 2022 after the FDA identified deficiencies related to the clinical package. The company has continued regulatory work on tebipenem, but regulatory approval and patent enforceability are separate questions. [FDA, 2022; Spero Therapeutics, 2022]

Which companies are challenging the patent?

No publicly established Paragraph IV challenge or litigated Hatch-Waxman case directed specifically to U.S. Patent 10,889,587 is identified in the available record.

That outcome is commercially unsurprising. Before FDA approval of a reference product, there is no ordinary ANDA-based market entry dispute. If tebipenem pivoxil hydrobromide receives approval, generic applicants could challenge listed patents through Paragraph IV certifications or seek a later entry date through Paragraph III certifications.

A future challenger would likely evaluate four routes:

  1. Develop a different tebipenem salt or polymorph.
  2. Use an amorphous or alternative crystalline form.
  3. Challenge the validity of claims 1-5 under anticipation, obviousness, enablement or indefiniteness.
  4. File an ANDA with a Paragraph IV certification against any listed patent.

What patent litigation and settlement risks exist?

There is no identified public settlement involving U.S. Patent 10,889,587. A future settlement could include:

  • a license to manufacture the claimed crystalline form;
  • a delayed generic entry date;
  • a covenant not to sue;
  • an authorized generic arrangement;
  • a manufacturing license limited to non-U.S. markets; or
  • a payment or supply agreement.

The most likely litigation issues would be claim construction of the XRPD peaks, the meaning of “at least 90%,” the relationship between the two alternative peak sets in claim 2, and whether a proposed generic form is materially different from the claimed form.

How does this patent compare with broader tebipenem protection?

Patent category Protection breadth Commercial role
Core tebipenem compound patent Potentially broad but likely expired or approaching expiry depending on priority Basic molecule protection
Salt-form patent Narrower, form-specific Protects a selected pharmaceutical salt
Crystalline-form patent 10,889,587 Narrow but potentially difficult to design around Protects solid-state API and product form
Formulation patent Product-specific Protects excipients, release profile, dosage form or stability
Method-of-use patent Indication-specific Protects treatment of cUTI or other infections
Manufacturing patent Process-specific Raises process substitution and scale-up barriers

U.S. Patent 10,889,587 is not a complete tebipenem exclusivity estate by itself. A commercial strategy would require a family-level review of related composition, process, formulation and therapeutic-use patents in the United States and other jurisdictions.

What licensing deals affect tebipenem?

Spero obtained rights to develop tebipenem pivoxil hydrobromide from Meiji Seika Pharma. The transaction gave Spero access to Meiji’s tebipenem program and supported development of an oral carbapenem for resistant bacterial infections. Public disclosures describe the relationship, but detailed commercial terms, including all milestone and royalty provisions, are not fully available in the patent record. [Spero Therapeutics, 2017]

The licensing relationship matters because patent ownership, development rights, regulatory rights and manufacturing rights may be divided among different entities. A patent assignment search should therefore be reviewed alongside the license agreement before evaluating freedom to operate or transaction value.

What generic entry risks exist?

The principal generic entry scenarios are:

Scenario 1: Same crystalline form

A generic applicant uses the patented hydrobromide form. This creates the highest infringement risk under claims 1-5 and potentially claims 6-8. A Paragraph IV challenge would likely focus on obviousness, indefiniteness, written description and analytical reproducibility.

Scenario 2: Alternative polymorph

A generic applicant develops a different polymorph or salt. This may avoid the crystalline-form claims but could still raise equivalence, formulation or process issues.

Scenario 3: Amorphous tebipenem pivoxil material

An amorphous product could avoid XRPD-defined crystalline claims if it lacks the claimed peaks. The commercial risk would depend on stability, dissolution, manufacturability and conversion into the patented form during storage.

Scenario 4: Different salt

A different salt could avoid the hydrobromide limitation. Its viability would depend on oral bioavailability, tolerability, chemical stability and regulatory comparability.

Scenario 5: Non-infringing product with equivalent clinical use

A generic may practice the same treatment claims while avoiding the crystalline-form claims. Method-of-use enforcement would be more difficult where the product label omits the patented indication or where physicians prescribe outside the label.

What is the geographic coverage?

U.S. Patent 10,889,587 provides rights only in the United States. It does not directly control manufacture, sale or use in Europe, Japan, China, India or other markets.

International protection must be assessed through the patent family and national-phase filings. The key jurisdictions for tebipenem commercial planning are:

  • United States;
  • European Patent Convention states;
  • Japan;
  • China;
  • South Korea;
  • India;
  • Canada; and
  • Australia.

The absence of a U.S. claim in a particular product strategy does not establish freedom to operate elsewhere. National patents can differ in claim scope, expiration, prosecution amendments and enforceability.

Key Takeaways

  • U.S. Patent 10,889,587 is primarily a crystalline-form patent for tebipenem pivoxil hydrobromide.
  • Claims 2 and 3 are the central API claims, defined by copper-source XRPD peaks.
  • Claims 6-8 extend protection into compositions, tablets and capsules.
  • Claims 9-16 cover treatment of bacterial infections, including urinary tract infections and specified Gram-negative pathogens.
  • The patent does not broadly cover every tebipenem pivoxil salt, polymorph or formulation.
  • The strongest design-around path is an alternative salt, polymorph or amorphous form that does not reproduce the claimed XRPD profile.
  • Claim 16 has an apparent dependency defect because it refers to claim 6 as a method claim.
  • No established Paragraph IV litigation or public settlement directed specifically to this patent is identified.
  • Tebipenem is a small molecule, so biosimilar substitution is not relevant. Generic ANDA risk is the relevant U.S. pathway.
  • The patent’s expected statutory term extends into the mid-2030s, subject to the official USPTO term calculation.
  • Commercial value depends on whether the claimed crystalline form is necessary for the approved product and whether related formulation, process and use patents provide additional exclusivity.

FAQs About U.S. Patent 10,889,587

Is tebipenem pivoxil hydrobromide protected by a composition-of-matter patent?

U.S. Patent 10,889,587 protects a specific crystalline hydrobromide form, not every chemical form of tebipenem pivoxil.

Can a generic avoid this patent by using a different tebipenem salt?

Potentially. A different salt would not literally satisfy the hydrobromide limitation, although other patents and regulatory requirements could still restrict development.

Does the patent cover tebipenem tablets?

Yes. Claims 6-8 cover compositions and dosage forms, including tablets and capsules, when they contain at least 90% of the claimed crystalline form in the relevant tebipenem salt component.

Is a biosimilar challenge possible for tebipenem?

No. Tebipenem pivoxil hydrobromide is a chemically synthesized small molecule. The expected abbreviated pathway is an ANDA, not a biosimilar application under the Public Health Service Act.

What analytical tests are most important in a patent dispute?

XRPD using copper K-alpha radiation is central. DSC, thermal transitions, water or solvent content, salt stoichiometry and solid-state stability would also be important in determining whether a product falls within claims 1-5.

References

  1. Food and Drug Administration. (2022). FDA complete response letter information relating to tebipenem pivoxil hydrobromide. U.S. Department of Health and Human Services.

  2. Spero Therapeutics, Inc. (2017). Corporate disclosure regarding development and licensing of tebipenem pivoxil hydrobromide. Spero Therapeutics.

  3. United States Patent and Trademark Office. (2021). U.S. Patent No. 10,889,587: Crystalline form of tebipenem pivoxil hydrobromide. U.S. Department of Commerce.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

  5. U.S. Code. (2023). 35 U.S.C. §§ 101, 112, 154, 156 and 271. U.S. Government Publishing Office.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,889,587

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline UTEBZI tebipenem pivoxil hydrobromide TABLET;ORAL 215960-001 Jun 17, 2026 RX Yes Yes 10,889,587 ⤷  Start Trial Y Y TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS CAUSED BY E. COLI, K. PNEUMONIAE, ECC, K. OXYTOCA, OR E. FAECALIS IN PATIENTS WHO HAVE LIMITED OR NO ALTERNATIVE ORAL TREATMENT OPTIONS WITH A TEBIPENEM PIVOXIL HBR SALT FORM OF CLAIM 2 OF US10889587 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,889,587

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018215687 ⤷  Start Trial
Australia 2020281120 ⤷  Start Trial
Brazil 112019015487 ⤷  Start Trial
Canada 3049690 ⤷  Start Trial
China 110234651 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.